Division of Reproductive Endocrinology & Infertility

One out of every eight couples will have trouble getting pregnant or sustaining a pregnancy. Our Division of Reproductive Endocrinology & Infertility contains one of the oldest, largest, and most successful fertility programs in the US. Led by international pioneers in reproductive medicine, our fertility team focuses both on cutting-edge innovation and patient experience. We provide a comprehensive range of services from routine infertility care to advanced in vitro fertilization, designing an individualized treatment plan tailored to each patient’s needs. Our physicians have successfully treated many patients who were turned away by other fertility centers. We also offer programs for those with specific complications, such as cancer and HIV.

Patient Care

We are committed to helping patients find ways to achieve pregnancy. In fulfilling this objective, world renowned physicians who are at the forefront of fertility research and teaching strive to provide patients with the best possible clinical care.

One of the hallmarks of the our fertility practice is the opportunity for patients to make the most innovative, cutting-edge fertility treatments available to a wide population of patients through affordable, accessible care. Expanded access takes place at many levels:

  • Clinical: by specializing in challenging cases (accepting patients despite poor prognosis profiles)
  • Financial: through our in-network managed care contracts (which minimize out-of-pocket expenses), patient financing options, and financial support through the New York State Infertility Demonstration Program grant
  • Geographic: services offered in two conveniently located facilities, on Columbus Circle in the heart of Manhattan, and in White Plains.

Advanced infertility care at our fertility practice involves an interdisciplinary team of physicians, nurses, nursing assistants, social workers, embryologists, and administrative, billing, reception, and support staff, all of whom are committed to our philosophy of care. Our team approach allows for consistent high-quality care as well as the benefits of collaboration and shared research.

Education

The division offers a fellowship in Reproductive Endocrinology & Infertility.

Research

Recent investigations in the Division of Reproductive Endocrinology and Infertility include the examination of celiac disease and infertility; Hodgkins Disease and ovarian reserve; ovarian reserve among breast cancer patients receiving chemotherapy; and the validation and clinical use of the anti-Mullerian Hormone (AMH) assay. The division hosts one of the largest egg donation programs in the country and clinical research related to recipients and egg donors is regularly performed. The Center for Women’s Reproductive Care has the performed the most assisted reproduction cycles in North America for patients infected with HIV, leading to regular publications related to their pregnancy outcomes and their clinical experience. Faculty in the division also have an active collaboration with the Department of Rehabilitation and Regenerative Medicine, and Genetics and Development, as demonstrated by 1) ongoing research on deriving a human embryonic stem cell line from non-viable embryos; and 2) research generated by Dr. Nataki Douglas’ Reproductive Scientist Development Program Fellowship focused on the molecular biology underlying reproductive tract anomalies.

Collaboration between our faculty and other institutions/sponsors includes: 1) human egg donation for the generation of diabetes specific embryonic stem cells, supported by a grant from the New York Stem Cell Foundation and the Naomi Berrie Diabetes Center at CUMC (leading to a publication in Nature in 2011); 2) fertility preservation for women with newly diagnosed cancer, in partnership with Fertile Hope; 3) the role of notch regulated angiogenesis in female reproduction with studies performed in collaboration with University of Valencia.

The division has pioneered the development of first-trimester screening and multi-fetal pregnancy reduction, and has recently completed the largest evaluation of microarray technology for prenatal diagnosis. This work continues with the development of a follow-up component to determine the phenotype of infants diagnosed in-utero with microdeletions and duplications. As part of this study, the division will develop a national registry of these cases.